Arbutus Biopharma (ABUS) Operating Leases (2019 - 2025)
Arbutus Biopharma (ABUS) has disclosed Operating Leases for 7 consecutive years, with $199000.0 as the latest value for Q4 2025.
- Quarterly Operating Leases fell 75.31% to $199000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $199000.0 through Dec 2025, down 75.31% year-over-year, with the annual reading at $199000.0 for FY2025, 75.31% down from the prior year.
- Operating Leases hit $199000.0 in Q4 2025 for Arbutus Biopharma, down from $391000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $2.5 million in Q1 2021 to a low of $199000.0 in Q4 2025.
- Historically, Operating Leases has averaged $1.5 million across 5 years, with a median of $1.6 million in 2023.
- Biggest five-year swings in Operating Leases: dropped 13.67% in 2021 and later plummeted 75.31% in 2025.
- Year by year, Operating Leases stood at $2.2 million in 2021, then decreased by 18.65% to $1.8 million in 2022, then decreased by 26.01% to $1.3 million in 2023, then plummeted by 39.99% to $806000.0 in 2024, then tumbled by 75.31% to $199000.0 in 2025.
- Business Quant data shows Operating Leases for ABUS at $199000.0 in Q4 2025, $391000.0 in Q3 2025, and $575000.0 in Q2 2025.